NASDAQ
XTLB

XTL Biopharmaceuticals Ltd ADR

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

XTL Biopharmaceuticals Ltd ADR Stock Price

Vitals

Today's Low:
$1.2300
Today's High:
$1.2300
Open Price:
$1.2300
52W Low:
$0.85
52W High:
$4.03
Prev. Close:
$1.2900
Volume:
210

Company Statistics

Market Cap.:
$0.007 billion
Book Value:
1
Revenue TTM:
$0.000 billion
Operating Margin TTM:
0%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
0%
Return on Assets TTM:
-9.31%
Return on Equity TTM:
34.4%

Company Profile

XTL Biopharmaceuticals Ltd ADR had its IPO on 2005-09-01 under the ticker symbol XTLB.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. XTL Biopharmaceuticals Ltd ADR has a staff strength of 0 employees.

Stock update

Shares of XTL Biopharmaceuticals Ltd ADR opened at $1.23 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.23 - $1.23, and closed at $1.23.

This is a -4.65% slip from the previous day's closing price.

A total volume of 210 shares were traded at the close of the day’s session.

In the last one week, shares of XTL Biopharmaceuticals Ltd ADR have increased by +23%.

XTL Biopharmaceuticals Ltd ADR's Key Ratios

XTL Biopharmaceuticals Ltd ADR has a market cap of $0.007 billion, indicating a price to book ratio of 1.264 and a price to sales ratio of -.

In the last 12-months XTL Biopharmaceuticals Ltd ADR’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.001 billion. The EBITDA ratio measures XTL Biopharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, XTL Biopharmaceuticals Ltd ADR’s operating margin was 0% while its return on assets stood at -9.31% with a return of equity of 34.4%.

In Q2, XTL Biopharmaceuticals Ltd ADR’s quarterly earnings growth was a negative -76% while revenue growth was a positive 0%.

XTL Biopharmaceuticals Ltd ADR’s PE and PEG Ratio

Forward PE
-
Trailing PE
4.161
PEG
0

Its diluted EPS in the last 12-months stands at $0.31 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into XTL Biopharmaceuticals Ltd ADR’s profitability.

XTL Biopharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of 29.64. Its price to sales ratio in the trailing 12-months stood at -.

XTL Biopharmaceuticals Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

XTL Biopharmaceuticals Ltd ADR ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

XTL Biopharmaceuticals Ltd ADR ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

XTL Biopharmaceuticals Ltd ADR’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, XTL Biopharmaceuticals Ltd ADR's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, XTL Biopharmaceuticals Ltd ADR paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$1.23
52-Week High
$4.03
52-Week Low
$0.85
Analyst Target Price
$30

XTL Biopharmaceuticals Ltd ADR stock is currently trading at $1.23 per share. It touched a 52-week high of $4.03 and a 52-week low of $4.03. Analysts tracking the stock have a 12-month average target price of $30.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About XTL Biopharmaceuticals Ltd ADR

The stock symbol (also called stock or share ticker) of XTL Biopharmaceuticals Ltd ADR is XTLB

The IPO of XTL Biopharmaceuticals Ltd ADR took place on 2005-09-01

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$5.1
-0.21
-3.95%
$0.89
0
+0.45%
$28.9
-1.16
-3.86%
$19.5
-0.72
-3.56%
$8.76
-0.36
-3.95%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company is headquartered in Ramat Gan, Israel.

Address

XTL BIOPHARMACEUTICALS LTD, C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, NY, US